Blocking nuclear receptor may cut off tumor blood supply

Jan 11, 2010

A new method of blocking the genesis of blood vessels that feed tumors may start with the nuclear receptor COUP-TFII (chicken ovalbumin upstream promoter-transcription factor II), said a pair of Baylor College of Medicine researchers who have studied the factor for more than 20 years.

In a report that went online today in the , a team led by Dr. Ming-Jer Tsai and Dr. Sophia Y. Tsai, both professors of molecular and cellular biology at BCM, described experiments in which the growth of new and tumors themselves were suppressed when COUP-TFII was not present. Their work demonstrates that the receptor directly regulates an angiogenic factor called Angiopoietin-1, which enhances the development of new blood vessels. (Angiogenesis means encouraging the formation of new blood vessels.) Without COUP-TFII, Angiopoietin-1 does not carry out its job efficiently meaning that neither the blood vessels nor the tumors grow, probably because there is limited vasculature to provide nourishment.

"This is important because it means we may be able to find an antagonist that can intervene to halt tumor growth and metastasis," said Dr. Ming-Jer Tsai. "Metastasis is the reason most cancer patients die."

At present, studies of vascular endothelial growth factor (VEGF) inhibitors are underway, he said. This factor also plays an important role in the growth of new blood vessels, and the drugs work against the tumors only for a short while.

"They only work on one pathway of angiogenesis," he said. This finding identifies another important pathway and another way to fight the tumors.

"We studied tumors in this model," said Dr. Sophia Tsai. She said the team plans to look at other kinds of solid tumors in which they believe COUP-TFII plays a role in angiogenesis.

Another benefit of knocking out COUP-TFII is that it is not needed in adult animals, she said. COUP-TFII is important in blood vessel formation in the developing fetus but plays no important role in maintaining the vasculature afterward, except in situations such as pregnancy or wound healing. The blood vessels of adult animals that lacked the factor remained normal.

She, Dr. Ming-Jer Tsai and their colleagues are also looking at ways to screen known biological chemicals for the ability to inhibit COUP-TFII.

Explore further: New fluorescent tools for cancer diagnosis

Related Stories

Vessel-thwarting antibody might help starve cancerous tumors

Nov 01, 2007

An antibody might offer a safe and effective complement to anti-cancer therapies designed to starve malignant tumors by pruning the blood vessels that feed them, researchers report in the November 2 issue of the journal Cell.

Recommended for you

New fluorescent tools for cancer diagnosis

7 hours ago

In recent years, microRNAs (miRNAs) and other non-coding RNAs are small molecules that help control the expression of specific proteins. In recent years they have emerged as disease biomarkers. miRNA profiles have been used ...

Modulating the immune system to combat metastatic cancer

7 hours ago

Cancer cells spread and grow by avoiding detection and destruction by the immune system. Stimulation of the immune system can help to eliminate cancer cells; however, there are many factors that cause the immune system to ...

How the EU could help more children survive cancer

12 hours ago

A leading expert in childhood cancer at The University of Nottingham is spearheading a Europe-wide lobby of the European Parliament to try to make it easier for doctors to develop and test new treatments on children and young ...

User comments : 0

More news stories

Galaxies fed by funnels of fuel

(Phys.org) —Computer simulations of galaxies growing over billions of years have revealed a likely scenario for how they feed: a cosmic version of swirly straws.

Google eyes emerging markets networks

Google has become deeply involved in a series of projects to build and operate wireless networks in emerging markets including sub-Saharan Africa and Southeast Asia, a report said Friday.